Lavipharm S.A.
Develops and markets pharmaceuticals, supplements, and transdermal delivery systems.
LAVI | AT
Overview
Corporate Details
- ISIN(s):
- GRS246003008
- LEI:
- 213800USC69CRPRGWJ15
- Country:
- Greece
- Address:
- AGIAS MARINAS STR, 19002 PAIANIA
- Website:
- https://lavipharm.com/
- Sector:
- Manufacturing
Description
Lavipharm S.A. is an integrated healthcare company engaged in the research, development, manufacturing, marketing, and distribution of pharmaceutical products. Established in 1911, the company offers a diverse portfolio that includes prescription (Rx) and over-the-counter (OTC) medicines, as well as food supplements. A key area of innovation for the company is its development of transdermal drug delivery systems. Lavipharm focuses on providing treatment options across several major therapeutic areas, including cardiology, neurology (Central Nervous System), urology, oncology, and chronic pain management.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-11-07 11:56 |
Ανακοίνωση Τροποποίησης προγράμματος stock options
|
Greek (modern) | 4.8 MB | ||
| 2025-09-18 19:39 |
Οικονομική έκθεση LAVIPHARM Α.Ε. (2025,Εξαμηνιαία,Ενοποιημένη)
|
Greek (modern) | 2.2 MB | ||
| 2025-09-18 16:50 |
ΔΕΛΤΙO ΤΥΠΟΥ ΟΙΚΟΝΟΜΙΚΑ ΑΠΟΤΕΛΕΣΜΑΤΑ Α΄ ΕΞΑΜΗΝΟΥ 2025
|
Greek (modern) | 156.3 KB | ||
| 2025-09-18 16:50 |
FINANCIAL RESULTS PRESS RELEASE FIRST HALF 2025
|
English | 99.2 KB | ||
| 2025-07-10 09:38 |
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 5 η’) αναφορ…
|
Greek (modern) | 216.3 KB | ||
| 2025-07-09 09:52 |
Έντυπο παροχής πληροφοριών Κανονισμού (ΕΕ) 2017/1129 (άρθρ. 1 παρ. 4 θ΄) αναφορ…
|
Greek (modern) | 205.1 KB | ||
| 2025-07-03 18:12 |
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΠΟΚΟΠΗΣ ΔΙΚΑΙΩΜΑΤΟΣ ΜΕΡΙΣΜΑΤΟΣ / ΠΛΗΡΩΜΗΣ ΜΕΡΙΣΜΑΤΟΣ/ ΠΡΟΜΕΡΙΣΜΑΤ…
|
Greek (modern) | 555.0 KB | ||
| 2025-07-03 18:00 |
ΔΕΛΤΙΟ ΤΥΠΟΥ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
|
Greek (modern) | 123.4 KB | ||
| 2025-07-03 18:00 |
PRESS RELEASE
|
English | 121.3 KB | ||
| 2025-07-03 17:35 |
ΑΝΑΚΟΙΝΩΣΗ ΕΠΙΤΡΟΠΗΣ ΕΛΕΓΧΟΥ
|
Greek (modern) | 503.0 KB | ||
| 2025-07-03 17:17 |
ΓΝΩΣΤΟΠΟΙΗΣΗ ΑΛΛΑΓΗΣ ΣΥΝΘΕΣΗΣ ΔΙΟΙΚΗΤΙΚΟΥ ΣΥΜΒΟΥΛΙΟΥ
|
Greek (modern) | 598.1 KB | ||
| 2025-07-03 17:05 |
ΑΝΑΚΟΙΝΩΣΗ ΓΙΑ ΤΙΣ ΑΠΟΦΑΣΕΙΣ ΓΕΝΙΚΗΣ ΣΥΝΕΛΕΥΣΗΣ
|
Greek (modern) | 195.1 KB | ||
| 2025-06-11 16:30 |
ΠΡΟΣΚΛΗΣΗ ΣΕ ΤΑΚΤΙΚΗ ΓΕΝΙΚΗ ΣΥΝΕΛΕΥΣΗ
|
Greek (modern) | 191.0 KB | ||
| 2025-05-15 16:19 |
Βασικά Οικονομικά Μεγέθη A Τριμήνου 2025
|
Greek (modern) | 118.2 KB | ||
| 2025-05-15 16:19 |
Financial Results Q1 2025
|
English | 92.6 KB |
Automate Your Workflow. Get a real-time feed of all Lavipharm S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Lavipharm S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Lavipharm S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
